ENLIVEN THERAPEUTICS, INC. Retained Earnings
ENLIVEN THERAPEUTICS, INC. (ELVN) had Retained Earnings of -$403.28 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-05
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$403.28M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$370.79M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$347.17M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$317.50M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$403.28M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | -$370.79M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | -$347.17M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | -$317.50M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | -$297.35M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | -$272.02M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | -$243.47M 10-K · filed 2026-03-03 | |
| 2024-09-30 | -$220.29M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | -$197.14M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | -$177.19M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | -$154.45M 10-K · filed 2025-03-13 | |
| 2023-09-30 | -$135.08M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | -$114.31M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | -$97.59M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | -$82.86M 10-K · filed 2024-03-14 | -$146.01M 10-K · filed 2023-02-10 |
| 2022-09-30 | -$178.19M 10-Q · filed 2022-10-25 | |
| 2022-06-30 | -$173.59M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | -$162.14M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | -$45.20M 8-K · filed 2023-06-23 | -$147.50M 10-K · filed 2022-03-15 |
| 2021-09-30 | -$133.18M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | -$119.53M 10-Q · filed 2021-08-06 | |
| 2021-03-31 | -$106.37M 10-Q · filed 2021-05-11 | |
| 2020-12-31 | -$96.11M 10-K · filed 2022-03-15 | |
| 2020-09-30 | -$84.59M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | -$72.17M 10-Q · filed 2020-08-14 | |
| 2020-03-31 | -$61.97M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | -$54.75M 10-K · filed 2021-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |